

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Offica: U.S. DEPARTMENT OF COMMERCE red to respond to a collection of information unless it contains a valid OMB Under the Paperwork Reduction Act of 1995, no persons are re

Substitute for form 1449A/PTO	Compl t if Known		
	Application Number	10/664,803	
INFORMATION DISCLOSURE	Filing Date	September 19, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Unchalee Kositprapa	
	Art Unit		
(use as many sheets as necessary)	Examiner Name		
Sheet 1 of 5	Attorney Docket Number	141-424	

			U.S. PAT	ENT DOCUMENTS	
Initials'		Document Number Number - Kind Code <sup>2</sup> (# known		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/A.S./		us-3,174,901	03-23-1965	Sterne	
1		us-3,960,949	06-01-1976	Ahrens et al.	
	AC		09-04-1979	Fong	
	AD		06-21-1983	Tice et al.	
_	AE		08-18-1987	Meguro et al. Colombo et al.	
$\neg$	AF		06-13-1989	Cofombo et al.	
	AG	us- 4,891,223	01-02-1990 11-06-1990	Ambegaonkar et al.	
	AH			Zentner et al.	
	AI	us- 5,294,770	03-15-1994	Riddle et al.	
T	AJ	us- 5,356,913	10-18-1994	Colca	
$\neg$	AK	US- 5,376,771	12-27-1994	Roy	
$\top$	AL	us-5,478,852	12-26-1995	Olefsky et al.	
$\neg$	AM	us- 5,602,133	02-11-1997	Antonucci et al.	
_	ΔNI	us-5,658,474	08-19-1997	Geerke	
	ÃÒ		10-28-1997	Savastano et al.	
	AP	us- 5,698,220	12-16-1997	Cardinal et al.	
T	AO.	us-5,719,188	02-17-1998	Colca	
V	AR	us- 5,859,037	01-12-1999	Whitcomb	
-	AS	us- 5,916,584	06-29-1999	O'Donoghue et al.	
/A.S./	AT	us. 5.952.356	09-14-1999	Ikeda et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials		Foreign Patent Document  Course Code3 -Number4 - Kind Code6 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relavant Passages or Relevant Figures Appear	т
	_					
	_					E
						-
						F
						F

Examiner Signature	-	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drew line through citation if not in

"EXAMINE: initial if reference considering, whether or not clatation is in conformance with MPEP 009. Unw line through clintoin if not in conformance and considered, include copy of this form which not communication to applicant."

1 Applicant's unique clatation designation number (optional). 3 See Kinds Codes of USEPT Posterill Documents at <a href="https://www.usclop.cog">www.usclop.cog</a> or MPEP

910.4. 2 Eiter (100% that is asseed the objective of the control in the posterior document, by the valent control in the posterior of the special of the region of the financial control in the posterior of the special of the special of the posterior of the special of the posterior English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Tree will very depending upon the needs of the individual case. Any commission on the annout of time you are required to complete this from shade the sent to the Chief Information Officer, U.S. Patert and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner For Paterts, Washington, DC 20231.



PTO/SEQUEA (10-01)
Approved for use through 10313020.0 OMB 0551-031
arrior Reddiction Act of 1995, no persons are required to respond to a collection of fromtains unliked like indians a valid OMB
arrior Reddiction Act of 1995, no persons are required to respond to a collection of fromtains unliked like indians as valid OMB Under the Papers

Substitut	e for form 1449A/PT	0			mplet if Known
INIEC	DIATION	٠.	COLOCUES !	Application Number	10/664,803
	INFORMATION DISCLOSURE		Filing Date	September 19, 2003	
STATEMENT BY APPLICANT		First Named Inventor	Unchalee Kositprapa		
	(use as many sheets as necessary)			Art Unit	
			s necessary)	Examiner Name	
Sheet	2	of	5	Attorney Docket Number	141-424

	_		U.S. PAT	ENT DOCUMENTS	
Examiner Initials		Document Number Number - Kind Code <sup>2</sup> (if known		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/A.S./	AU		09-21-1999	Moeckel et al.	
	ΑV		01-04-2000	Whitcomb	
	AW		02-29-2000	Timmins et al.	
	AX	us-6,099,859	08-08-2000	Cheng et al.	
	ΑY	us-6,153,632	11-28-2000	Rieveley	
	AZ		02-20-2001	Byrd et al.	
	BA	us- 6,248,363	06-19-2001 09-18-2001	Patel et al.	-
	BB	us-6,291,495		Rieveley	
	BC		10-02-2001	Cutie et al.	
	BD	us- 6,329,403	12-11-2001	Odaka et al.	
	BE	us- 6,383,471	05-07-2002	Chen et al.	
	BF	US-6,403,121	06-11-2002	Adjei et al.	
	BG	us- 2002/0071866	06-13-2002	Geerke	
	BH	US-6,451,342	09-17-2002	Adiei et al.	
	BI	us-6,475,521	11-05-2002	Timmins et al.	
	ΒĴ	us- 6,524,621	02-25-2003	Adjei et al.	
VI	BK	US-2003/0113371	06-19-2003	Dhawan et al.	
V	BL	Us- 2003/0118647	06-26-2003	Seth	
10.0.	BM	us- 2003/0118649	06-26-2003	Gao et al.	
A.S./	RN	us. 6.599.284	07-29-2003	Faour	

		FORI	EIGN PATENT D	OCUMENTS		_
	No.1	Foreign Patent Document  County Code 3 - Number 4 - Kind Code 5 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Passages or Relevant Figures Appear	_ T
/A.S./	ĈĀ	WO 96/09823 '	04-04-1996	Luo et al.		
1	CB	WO 98/11879	03-26-1998	Shell et al.		Г
	CC	WO 98/55107 ~	12-10-1998	Shell et al.		Г
	CD	WO 99/47128 /	09-23-1999	Timmins et al.		
	CE.	WO 99/55320	11-04-1999	Nishii et al.		
	CF	WO 00/28989	05-25-2000	Lewis et al.		П
	CG	WO 00/72827 r	12-07-2000	Straub et al.		
VI	CH	WO 01/35940	05-25-2001	Lewis et al.		
	CI	WO 01735941	05-25-2001	Lilliot et al.		
A.S./	CJ	WO 01/82875	11-08-2001	Cutie et al.		Г

Signature			Considered	
*EYAMINED	initial if reference considered whether or no	t citation is in conformance	with MDED 600	Draw line through citation if not in

\*ExAMINET: intil all returnous considered, whether or not lotation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered include copy of this town with next communication to applicant.

\*Applicant's unique citation designation number (optional), \*2 see Kristi Codes of USPPT Drater Coopured is 1 year-purpless, or MPEP (and the common of the commo

Burden Hyar Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual cases. Any commentate on the ancest of their separate representations of the complete the stem should be sent to the Chief information Officer, U.S. Patient and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, DC 20231.



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent end Trademerk Office: U.S. DEPARTMENT OF COMMERCE
red to respond to a collection of information unless it contains a valid OMB Under the Paperwork Reduction Act of 1995, no persons are requestroil number.

Complet if Known Substitute for form 1449A/PTO 10/664.803 Application Number INFORMATION DISCLOSURE September 19, 2003 Unchalee Kositprapa Filing Date STATEMENT BY APPLICANT First Named Inventor Art Unit (use as many sheets as necessary) Examiner Name of 5 Attorney Docket Number 141-424 Sheet 3

			U.S. PATI	ENT DOCUMENTS	
Examiner	Cito	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials		Number - Kind Code <sup>2</sup> (if known		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
ALCOHOL: UNIVERSITY OF THE PARTY OF THE PART	1	US-			
		US-			
		US-			
		US-			
	-	US-			
		US-			
	1	US-			
		US-			

		FORI	EIGN PATENT D	OCUMENTS		-
Examiner		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevent Passages	l
Initials	No.1	County Code3 -Number4 - Kind Code <sup>6</sup> (# Anown)	MM-DD-YYYY		or Relavant Figures Appear	Т
7A.S./	CK	WO 02/28181	04-11-2002	Gidwani et al.		
	CL	WO 03/004009	01-16-2003	Matharu et al.		
V	CM	WO 03/035029	05-01-2003	Louie-Helm et al.		Г
	CN	WO 03/047529	06-12-2003	Seth et al.		Г
/A.S./		EP 0 169 105	01-22-1986	Zentner et al.	7	Γ
	Cp.	ED 0 383 360	09 21 1988	Wiernsperger et al.	Not in Engl:	r
7A.S.	co	EP 0 381 181	08-08-1995	Wenzel et al.		Γ
/A.S./	CR	EP 0 749 751	12-27-1996	Ikeda et al.		L
/A.S./ /A.S.	CS	EP 0 753 298	11-21-2001	Tsujita et al.		
7A.S.	CT	EP 0 781 129	07-02-2003	Moeckel et al.		Γ

Signature		Considered	
	initial if reference considered, whether or not citation is in conformance		Drew line through citation if not in

conformace and not considered. Technical control of the constitution of the constituti



PTC/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DE PARTMENT OF COMMERCE ited to respond to a collection of information unless it contains a valid OMB

control number.

Examiner

SUBSTRUITE OF FORM 14498/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Compl t if Known
Application Number 10/664,803
Filing Date September 19, 2003
First Named Inventor
Group Art Unit
Examiner Name
Attorney Docket Number 141-424

(use as many sheets as necessary)
Sheet 4 of 5

Examiner Include name of the author (in CAPITAL LETTERS), title of the airclack when appropriate), title of the intitiate No.1 Item (book, magazine, journal, sarial, symposium, catalog, etc.), date, page(s), volume-issue number(s), notificther ofto and/or country where outlished		1	
A.S./	DA	P. Karttunen et al., International Journal of Clinical Pharmacology, Therapy and Toxicology, "The pharmacokinetics of metformin: a comparison of the	
		properties of a rapid release and a sustained-release preparation" Vol. 21, No. 1-1983, pp. 31-36.	
	DB	P.J. Pentikainen, International Journal of Clinical Pharmacology, Therapy and Toxicology, "Bioavailability of metformin. Comparison of solution, rapidly dissolving-tablet, and three-sustained-release-products", Vol24, No4—1986, pp. 213-220.	
	DC	Finnish Monograph of the Diformin®, Retard tablet, with English translation	1
		O.J. Lucis, MD, Ph.D., MSC, Canada Medical Association J. Pharmacologic Update "The status of metformin in Canada" Vol. 128, January 1, 1983, pgs. 24-26.	
	DE	G. Belcher and D.R. Matthews Experiment and Clinical Endrocrinology & Diabetes, "Safety and tolerability of pioglitazone" Suppl. 2 (2000) pgs. 267-273.	-
		Daniel Einhom, MD et al., Clinical Therapeutics "Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placeboe-Controlled Study", "Vol. 22, No. 12, 2000 pps. 1395-1413.	
$\sqrt{}$		National Institute for Clinical Excellence Technology Appraisal Guidance - No. 21, "Guidance on the Use of Pioglitazone for Type 2 Diabetes Mellitus" March 2001. pps. 1-13.	
/A.S./	DH	The Pharmaceutical Journal, Vol. 265, No. 7122, p. 710 November 11, 2000 Clinical (abstract only).	

ι	Signature	Considere	il
	AMINER: Initial if reference considered, whether or not citation		e through citation if not in conformance

Date

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Then will vary depending upon the needs of the inclination comments on the amount of time you can required to complete this form should be sent to the Child Information Chince, U.S. Petert and Trademark-Office, Westington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Potents, Westington, DC 20231.



Approved for use through 10312002.0MB (10-01)

U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for from 1449BPTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as mern sheets as necessary)

Sheet | 5 | 5 | 5 |

Sheet | 5 | 6 | 5 |

Application Number | 10/654,803 |

Filine Date | 5 |

Filine Date |

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exeminer Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-lesue unimprefs), publisher, cryandforcountry whem published.	T <sup>2</sup>	
/A.S./	DI	Product Labeling for Glucophage® XR (July 2002).		
	DJ	ADA Professional Section Member Supplement 047 and 0503-506 (Poster) p. A110; A117		
$\forall$	DK	Website www.findarticles.com, Clinician Reviews, "Insulin-Sensitizing Diabetes Agent" September 1999.		
/A.S./	DL	ACTOS® product label, Physician's Desk Reference, 55th Edition, pp. 3171-3175		
	DIVI	Kole Liste No. 11031 the Neolicalment Nechlaber of NeDDL-B, ChemFinatur. Not- Fabrik Pütter GmbH & Co. KG, Kuhloweg 37-39 Iserlohn/Germany, Editio Cantor Verlag für Medizin und Naturwissenschaften GmbH, 1993.	ir	English

Examiner	/Aradhana Sasan/	Date	03/17/2008	
Signature		Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Transitation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Orlino, U.S. Petent of Tredemark—Orlice, Weshington, D. (2023). DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Weshington, D. (2023).